Senzime AB (SEZI) - Net Assets

Latest as of March 2026: Skr283.50 Million SEK ≈ $30.51 Million USD

Based on the latest financial reports, Senzime AB (SEZI) has net assets worth Skr283.50 Million SEK (≈ $30.51 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr350.01 Million ≈ $37.67 Million USD) and total liabilities (Skr66.51 Million ≈ $7.16 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Senzime AB to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr283.50 Million
% of Total Assets	81.0%
Annual Growth Rate	21.03%
5-Year Change	102.19%
10-Year Change	130.88%
Growth Volatility	46.75

Senzime AB - Net Assets Trend (2005–2025)

This chart illustrates how Senzime AB's net assets have evolved over time, based on quarterly financial data. See how many days can Senzime AB fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Senzime AB (2005–2025)

The table below shows the annual net assets of Senzime AB from 2005 to 2025. For live valuation and market cap data, see Senzime AB market cap and net worth.

Year	Net Assets	Change
2025-12-31	Skr304.46 Million ≈ $32.76 Million	-11.97%
2024-12-31	Skr345.86 Million ≈ $37.22 Million	-7.89%
2023-12-31	Skr375.48 Million ≈ $40.41 Million	+43.36%
2022-12-31	Skr261.90 Million ≈ $28.18 Million	+73.93%
2021-12-31	Skr150.58 Million ≈ $16.20 Million	-34.91%
2020-12-31	Skr231.35 Million ≈ $24.90 Million	+41.33%
2019-12-31	Skr163.69 Million ≈ $17.62 Million	-2.22%
2018-12-31	Skr167.41 Million ≈ $18.02 Million	+19.19%
2017-12-31	Skr140.46 Million ≈ $15.12 Million	+6.51%
2016-12-31	Skr131.87 Million ≈ $14.19 Million	+187.86%
2015-12-31	Skr45.81 Million ≈ $4.93 Million	+3.92%
2014-12-31	Skr44.08 Million ≈ $4.74 Million	+17.67%
2013-12-31	Skr37.46 Million ≈ $4.03 Million	+17.12%
2012-12-31	Skr31.99 Million ≈ $3.44 Million	+14.79%
2011-12-31	Skr27.87 Million ≈ $3.00 Million	+27.25%
2010-12-31	Skr21.90 Million ≈ $2.36 Million	+31.80%
2009-12-31	Skr16.61 Million ≈ $1.79 Million	-9.39%
2008-12-31	Skr18.34 Million ≈ $1.97 Million	+96.51%
2007-12-31	Skr9.33 Million ≈ $1.00 Million	+23.62%
2006-12-31	Skr7.55 Million ≈ $812.29K	+12.74%
2005-12-31	Skr6.70 Million ≈ $720.49K	--

Equity Component Analysis

This analysis shows how different components contribute to Senzime AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 77507600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	Skr19.65 Million	6.45%
Other Comprehensive Income	Skr-374.00K	-0.12%
Other Components	Skr1.06 Billion	348.24%
Total Equity	Skr304.46 Million	100.00%

Senzime AB Competitors by Market Cap

The table below lists competitors of Senzime AB ranked by their market capitalization.

Company	Market Cap
Vakrangee Limited NSE:VAKRANGEE	$74.62 Million
SRV Group plc HE:SRV1V	$74.64 Million
e-LITECOM CO. Ltd KQ:041520	$74.66 Million
AGROB Immobilien AG F:AGR	$74.67 Million
Cintac SN:CINTAC	$74.58 Million
CHAPEL DOWN GRP PLC LS-05 F:1U6	$74.57 Million
Shanghai Shibei Hi-Tech Co Ltd B SHG:900902	$74.54 Million
Siebert Financial Corp NASDAQ:SIEB	$74.51 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Senzime AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 345,857,000 to 304,461,000, a change of -41,396,000 (-12.0%).
Net loss of 137,419,000 reduced equity.
Share repurchases of 104,243,000 reduced equity.
New share issuances of 104,243,000 increased equity.
Other comprehensive income decreased equity by 9,476,000.
Other factors increased equity by 105,499,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr-137.42 Million	-45.14%
Share Repurchases	Skr104.24 Million	-34.24%
Share Issuances	Skr104.24 Million	+34.24%
Other Comprehensive Income	Skr-9.48 Million	-3.11%
Other Changes	Skr105.50 Million	+34.65%
Total Change	Skr-	-11.97%

Book Value vs Market Value Analysis

This analysis compares Senzime AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.13x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 1.44x to 2.13x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2009-12-31	Skr3.07	Skr4.41	x
2010-12-31	Skr2.97	Skr4.41	x
2011-12-31	Skr3.03	Skr4.41	x
2012-12-31	Skr2.78	Skr4.41	x
2013-12-31	Skr2.87	Skr4.41	x
2014-12-31	Skr3.03	Skr4.41	x
2015-12-31	Skr2.97	Skr4.41	x
2016-12-31	Skr4.66	Skr4.41	x
2017-12-31	Skr3.51	Skr4.41	x
2018-12-31	Skr3.74	Skr4.41	x
2019-12-31	Skr3.22	Skr4.41	x
2020-12-31	Skr4.06	Skr4.41	x
2021-12-31	Skr2.38	Skr4.41	x
2022-12-31	Skr3.88	Skr4.41	x
2023-12-31	Skr4.07	Skr4.41	x
2024-12-31	Skr2.83	Skr4.41	x
2025-12-31	Skr2.07	Skr4.41	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Senzime AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -45.14%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -132.11%
• Asset Turnover: 0.28x
• Equity Multiplier: 1.21x
Recent ROE (-45.14%) is below the historical average (-22.42%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2009	-10.36%	-102.10%	0.08x	1.27x	Skr-3.38 Million
2010	-10.75%	-137.70%	0.07x	1.18x	Skr-4.54 Million
2011	-7.54%	-115.59%	0.06x	1.14x	Skr-4.89 Million
2012	-13.73%	-1472.30%	0.01x	1.04x	Skr-7.59 Million
2013	-14.94%	-453.26%	0.03x	1.03x	Skr-9.34 Million
2014	-14.05%	-1144.16%	0.01x	1.05x	Skr-10.60 Million
2015	-16.55%	-4966.72%	0.00x	1.04x	Skr-12.16 Million
2016	-7.14%	-578.13%	0.01x	1.19x	Skr-22.60 Million
2017	-9.27%	-6892.59%	0.00x	1.18x	Skr-27.07 Million
2018	-15.30%	-797.17%	0.02x	1.18x	Skr-42.36 Million
2019	-20.57%	-501.79%	0.04x	1.15x	Skr-50.04 Million
2020	-20.51%	-508.14%	0.04x	1.12x	Skr-70.58 Million
2021	-54.55%	-748.11%	0.06x	1.16x	Skr-97.20 Million
2022	-50.67%	-945.56%	0.04x	1.23x	Skr-158.89 Million
2023	-35.73%	-375.20%	0.08x	1.15x	Skr-171.70 Million
2024	-34.33%	-203.03%	0.14x	1.23x	Skr-153.31 Million
2025	-45.14%	-132.11%	0.28x	1.21x	Skr-167.87 Million

Industry Comparison

This section compares Senzime AB's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $154,871,216
Average return on equity (ROE) among peers: -59.99%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Senzime AB (SEZI)	Skr283.50 Million	-10.36%	0.23x	$74.61 Million
Acarix A/S (ACARIX)	$100.54 Million	-51.52%	0.18x	$31.21 Million
Arcoma AB (ARCOMA)	$49.53 Million	2.76%	0.92x	$13.61 Million
Bactiguard Holding AB (publ) (BACTI-B)	$387.11 Million	-0.84%	0.62x	$54.96 Million
BICO Group AB (BICO)	$549.64 Million	0.11%	0.10x	$124.14 Million
Boule Diagnostics AB (BOUL)	$192.86 Million	6.07%	0.41x	$13.37 Million
CellaVision AB (CEVI)	$206.18 Million	29.00%	0.24x	$351.14 Million
Clinical Laserthermia Systems AB (publ) (CLS-B)	$3.68 Million	-18.24%	0.50x	$11.99 Million
Chordate Medical Holding AB (CMH)	$15.09 Million	-193.46%	0.46x	$29.05K
C-Rad AB (publ) (CRAD-B)	$38.03 Million	-55.21%	0.62x	$127.56 Million
Duearity AB (DEAR)	$6.06 Million	-318.56%	0.99x	$331.97K

About Senzime AB

ST:SEZI Sweden Medical Devices

Market Cap

$74.61 Million

Skr693.32 Million SEK

Market Cap Rank

#20433 Global

#367 in Sweden

Share Price

Skr4.41

Change (1 day)

-1.45%

52-Week Range

Skr4.10 - Skr7.27

All Time High

Skr26.50